NextCure

$11.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.49 (+4.47%) Today

$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell NextCure and other stocks, options, and ETFs commission-free!

About NXTC

NextCure, Inc. Common Stock, also called NextCure, is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD. The listed name for NXTC is NextCure, Inc. Common Stock.

CEO

Michael S. Richman

Employees

Headquarters

Beltsville, Maryland

Founded

2015

Market Cap

315.21M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

328.95K

High Today

$11.76

Low Today

$10.90

Open Price

$10.96

Volume

362.55K

52 Week High

$70.98

52 Week Low

$7.91

Collections

Analyst Ratings

44%

of 9 ratings

Buy

44%

Hold

56%

Sell

NXTC Earnings

-$4.46

-$2.86

-$1.27

$0.33

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 11, After Hours